PCNA and prostate cancer: Additionally, Fritz et al. reported that administration of the SCD1 inhibitor, BZ36, a nicotinamide derivative, in mice that bore prostate cancer xenografts slowed tumor growth and generated a limited population of tumor cells that were positive for the proliferation-associated marker proliferating cell nuclear antigen (PCNA) [81].